The Discovery clinical trial which tested this product was initially launched in March 2020 by Inserm to assess possible treatments for Covid-19.
- The termination of the trial is based on the lack of evidence of the efficacy of Remdesivir after 15 days and on a very low probability of concluding with the inclusion of additional participants.
“Discovery clinical trial stops testing Remdesivir against Covid-19, due to lack of evidence of its effectiveness”, announces Inserm in a press release.
The Discovery clinical trial was initially launched in March 2020 by Inserm to assess possible treatments for Covid-19. On January 13, 2021, the trial’s Data and Safety Monitoring Boards (DSMB) assessed all data in an interim report, based on 776 patients. 389 had received Remdesivir, and 387 standard care. The efficacy of the treatment was evaluated after 15 days and measured on the WHO reference scale. “Following this assessment, the DSMB recommended suspending patient enrollment in the therapeutic arm testing Remdesivir,” explain the Inserm researchers.
Continuation of the test on a combination of two monoclonal antibodies
This recommendation is based on “the lack of evidence of the efficacy of Remdesivir after 15 days and on a very low probability of concluding with the inclusion of additional participants”, they specify. There was also no evidence of treatment efficacy at day 29.
Discovery’s trial will continue in 80 centers in 14 European countries to evaluate a combination of two monoclonal antibodies targeted against the SARS CoV2 virus. “In addition to the deployment of vaccines, it remains essential to find new drugs and provide solid evidence of their effectiveness on patients affected by Covid-19”concludes Inserm.
.
